China Universal Asset Management Co. Ltd. Purchases Shares of 65,698 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

China Universal Asset Management Co. Ltd. bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 65,698 shares of the company's stock, valued at approximately $520,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMRX. Gladius Capital Management LP acquired a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $37,000. Quest Partners LLC bought a new stake in shares of Amneal Pharmaceuticals during the third quarter worth $84,000. Janney Montgomery Scott LLC acquired a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth $121,000. Quadrature Capital Ltd bought a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $169,000. Finally, Aigen Investment Management LP acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $213,000. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on AMRX shares. Piper Sandler upped their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, November 11th. StockNews.com cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $10.00.

Amneal Pharmaceuticals Stock Down 0.1 %

AMRX traded down $0.01 during midday trading on Thursday, hitting $7.97. 1,382,295 shares of the company were exchanged, compared to its average volume of 1,222,845. The firm's 50 day moving average price is $8.15 and its 200-day moving average price is $8.23. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $9.48. The firm has a market capitalization of $2.47 billion, a P/E ratio of -11.72 and a beta of 1.10.

Insider Buying and Selling

In other news, SVP Jason B. Daly sold 43,657 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the transaction, the senior vice president now directly owns 13,665 shares of the company's stock, valued at approximately $117,655.65. This trade represents a 76.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gautam Patel sold 80,000 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $8.14, for a total value of $651,200.00. Following the completion of the transaction, the director now directly owns 1,888,886 shares in the company, valued at $15,375,532.04. This represents a 4.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 203,657 shares of company stock valued at $1,667,887 over the last ninety days. 26.56% of the stock is owned by company insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.